Wegovy Denied by Insurance? What to Include in Your Appeal Letter

AppealWise · Updated October 2026 · 6 min read

Wegovy (semaglutide) is expensive — roughly $1,300+ per month without coverage — so a denial stings. But plan data and external-review rulings show most Wegovy denials are reversible when the appeal packet answers the exact denial reason. Here's exactly what goes into a letter that gets a second look.

The 6 things every Wegovy appeal letter must include

1. Patient + plan identifiers — full name, date of birth, member ID, and any claim/authorization or case number from the denial.
2. The denial reason quoted verbatim — "not medically necessary," "step therapy," "non-formulary." Copy it word for word from the letter.
3. Diagnosis documentation — obesity (and any comorbidities: hypertension, diabetes, sleep apnea, cardiovascular risk) with ICD-10 codes if available.
4. Prior treatment history — diet and exercise programs, prior medications, duration of each, and response. This directly rebuts "step therapy" denials.
5. The medical-necessity argument — why Wegovy specifically is appropriate: FDA-approved indication, your BMI, and the clinical rationale your prescriber supports.
6. Provider signature — a treating physician's support letter is the single biggest success factor.

Match your argument to the denial type

• "Not medically necessary" → the fix is documentation: chart notes, BMI history, comorbidity records. Add the doctor letter.
• Step therapy → document why alternatives failed or are contraindicated (side effects, intolerance, poor response).
• Non-formulary → request a formulary exception based on medical necessity and lack of a suitable alternative on the list.
• Dose/count limits → a corrected prescription and provider note explaining the titration schedule often solves it.

Deadlines that matter

Internal appeal: at least 180 days from the denial letter date. Insurer response: 30 days pre-service (72 hours urgent), 60 days post-service. External review: request within roughly 4 months after an internal denial — free, and the decision binds the insurer.